News

Stay up to date on the latest company news and scientific headlines.

Interleukin Genetics Reports First Quarter 2016 Financial Results

Two Agreements Year to Date to Incorporate PerioPredict® into Employee Benefit Plans

Conference call today at 8:30 AM Eastern Standard time
WALTHAM, Mass. – May 16, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal first quarter of 2016, ended March 31, 2016.

“Our focus at Interleukin Genetics over the past year has been on developing a commercial plan that will drive market adoption of PerioPredict®, our genetic test that identifies individuals with an increased risk for severe and progressive periodontitis due to a life-long genetic predisposition to over-produce Interleukin-1 (IL-1), a key mediator of inflammation. Elevated inflammation is implicated in numerous chronic diseases,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.

“Our enhanced […]

Interleukin Genetics Announces Conference Call to Discuss First Quarter 2016 Financial Results

WALTHAM, MA – May 10, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Monday, May 16, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company’s first quarter ended March 31, 2016 financial results.

Monday, May 16th, 8:30 a.m. Eastern Time

Dial in (domestic):                  877-324-1976
Dial in (international):            631-291-4550
Conference ID:                      5524079

A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets […]

Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases

Interleukin Genetics Utilizes Genetic Patterns in Investigational Drug Response Evaluation

WALTHAM, MA – May 4, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin’s IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects.  The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.

“Working with Eleven Biotherapeutics to […]

Interleukin Genetics Receives Notice of Allowance for United States Patent for PerioPredict® Genetic Risk Test

Interleukin adds key component to plan for intellectual property protection

WALTHAM, MA – April 26, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced that it has received a notice of allowance for a patent by the United States Patent and Trademark Office (USPTO) for an application covering the Company’s PerioPredict® Genetic Risk Test. The application, entitled “Method for Determining Severity and Progression of Periodontal Disease,” has allowed claims covering methods of determining a subject’s genotype to ascertain their risk of developing severe periodontal disease and the treatment of those at risk to slow the progression of the disease.

“This allowed application […]

PerioPredict® Genetic Risk Test Incorporated Into Freedom Dental Plan

Delivers additional access to fully covered preventative care for patients at increased risk for periodontal disease identified through PerioPredict

WALTHAM, MA – April 21, 2016Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced it has signed an agreement with Reimbursement Specialists, Inc., a Comprehensive Benefit Administrators (CBA) company and leading provider of benefits management services, to include coverage for Interleukin’s PerioPredict® Genetic Risk Test as part of CBA’s Freedom Dental Plan.

PerioPredict identifies individuals at increased risk for severe periodontitis due to a genetic tendency to over-produce chronic inflammation, an underlying root cause of many chronic diseases. The test […]

Interleukin Genetics Announces Clarification of Commercial Test Compliance

Interleukin and the U.S. Food and Drug Administration have reached alignment on compliance status of Interleukin’s genetic tests

WALTHAM, MA – April 5, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced the results of discussions with the U.S. Food and Drug Administration (FDA) in response to an Untitled Letter issued by the FDA on November 4, 2015 and a meeting on February 3, 2016 with personnel within FDA’s Office of In Vitro Diagnostics and Radiological Health (OIR) to discuss Interleukin’s written response to OIR with respect to the Untitled Letter.  Interleukin believes it has maintained a constructive relationship with the […]

Interleukin Genetics Announces Clinical Study to Evaluate Impact of PerioPredict® Genetic Risk Testing on Dental Patient Engagement and Preventative Care

Study aims to broaden evidence in support of medical and economic value of PerioPredict® genetic testing platform

WALTHAM, MA – March 29, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced Institutional Review Board (IRB) approval for a clinical study to assess the impact of the Company’s PerioPredict Genetic Risk Test on dental patient engagement for more preventive dental care. The study will build on Interleukin Genetics’ evidence base in support of the medical and economic value of the PerioPredict genetic testing platform.

PerioPredict identifies individuals at increased risk for severe periodontitis because they have a genetic tendency to over-produce chronic inflammation, […]

Interleukin Genetics Reports Fourth Quarter and Year-End 2015 Financial Results

Progress in Executing Commercial Plan Underscored by Recent Agreement with Metagenics, Inc.

Conference Call and Webcast Today at 8:30 a.m. EDT

WALTHAM, MA – March 17, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2015.
“2015 was an important year for Interleukin Genetics, as we focused on developing and executing a significantly updated strategic and operational plan centered on the medical value of our genetic test, PerioPredict®,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics. “We position PerioPredict as the cornerstone of enhanced benefits designs and employer-sponsored wellness initiatives to identify high-risk individuals for proactive outreach and personalized care. We believe these programs […]

Interleukin Genetics Appoints Global Clinical Advisory Board To Guide Enhanced Healthcare Through Targeted Management of Systemic Inflammation

World-renowned team to advise on building practical population health initiatives

 

WALTHAM, MA – March 16, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases that reduce longevity and life quality, today announced the appointment of leading experts to its newly formed Clinical Advisory Board to advise the Company on clinical programs aimed at demonstrating the clinical and health economic benefits of targeted prevention and treatment of periodontitis, a common local inflammatory disease, in the management of several chronic diseases that affect widespread tissues and organs of the body.

“We are extremely pleased to bring together a ‘dream team’ of international experts at the intersection of systemic and […]

Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results

WALTHAM, MA – March 15, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Thursday, March 17, 2016, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s fourth quarter and year-end 2015 financial results.

Thursday March 17th, 8:30 a.m. (ET)

Dial in (domestic):                  877-324-1976

Dial in (international):            631-291-4550

Conference ID:                        62665317

A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com. 

 

About Interleukin Genetics.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions.  The products empower individuals and their healthcare providers to manage […]